Â鶹´«Ã½

    Advertisement
    WHDH-TV, Massachusetts15:27Ozempic FDA Pharma
    Medpage Today13:43Ozempic FDA Pharma
    Channel NewsAsia20:33Singapore Pharma Business (US)
    The Straits Times00:47Singapore Pharma Business (US)
    Pharmaceutical Technology09:13Eli Lilly Mounjaro Pharma
    Pharmacy Times09:16Eli Lilly Mounjaro Pharma
    pharmaphorum05:58Ozempic Tirzepatide Pharma
    The West Australian17:55Ozempic Tirzepatide Pharma
    Proactive Investors (Canada)15:48AI Business (US) Tesla
    Yahoo! UK & Ireland05:28AI Business (US) Tesla
    Fortune15:18Amycretin Ozempic Pharma
    Fortune06:37Amycretin Ozempic Pharma
    Benzinga08:11Pharma
    The Motley Fool07:08Pharma
    JD Supra16:11Sanofi Insulin FDA
    pharmaphorum04:45Sanofi Insulin FDA
    Yesterday
    Boston Globe18:22 21-Feb-25
    Yahoo! UK & Ireland16:23 21-Feb-25
    Money Morning15:36 21-Feb-25
    WHDH-TV, Massachusetts15:27 21-Feb-25
    Fortune15:18 21-Feb-25
    Medpage Today13:43 21-Feb-25
    TipRanks13:06 21-Feb-25
    Santa Cruz Sentinel, California13:00 21-Feb-25
    Quartz12:16 21-Feb-25
    Invezz11:43 21-Feb-25
    The Motley Fool11:38 21-Feb-25
    FiercePharma11:22 21-Feb-25
    Wall Street Pit11:16 21-Feb-25
    WIRED11:02 21-Feb-25
    KELO TV10:31 21-Feb-25
    Pharmacy Times10:12 21-Feb-25
    PR Newswire (Press Release)10:09 21-Feb-25
    Bloomberg Law09:19 21-Feb-25
    FiercePharma08:49 21-Feb-25
    University of Southern Denmark08:41 21-Feb-25
    Yahoo! UK & Ireland06:02 21-Feb-25
    PR Newswire (Press Release)05:54 21-Feb-25
    Channel NewsAsia02:02 21-Feb-25
    Seeking Alpha00:39 21-Feb-25
    Seeking Alpha00:39 21-Feb-25
    In the last 7 days
    BBC21:46 20-Feb-25
    GlobeNewswire (Press Release)20:31 20-Feb-25
    JD Supra16:11 20-Feb-25
    Scrip Pharma Intelligence12:03 20-Feb-25
    GlobeNewswire (Press Release)08:33 20-Feb-25
    AsiaOne03:30 20-Feb-25
    The Straits Times00:47 20-Feb-25
    Channel NewsAsia20:33 19-Feb-25
    GlobeNewswire (Press Release)13:03 19-Feb-25
    GlobeNewswire (Press Release)11:11 19-Feb-25
    Pharmaceutical Technology09:13 19-Feb-25
    KELO TV07:09 19-Feb-25
    pharmaphorum06:30 19-Feb-25
    DD News06:23 19-Feb-25
    Yahoo! US06:14 19-Feb-25
    Law36021:14 18-Feb-25
    FierceBiotech15:09 18-Feb-25
    FiercePharma11:52 18-Feb-25
    Scrip Pharma Intelligence11:02 18-Feb-25
    KELO TV10:39 18-Feb-25
    Entrepreneur Magazine07:21 18-Feb-25
    PR Newswire (Press Release)05:49 18-Feb-25
    pharmaphorum04:45 18-Feb-25
    PR Newswire (Press Release)16:36 17-Feb-25
    JD Supra12:22 17-Feb-25
    Evening Standard07:50 17-Feb-25
    The Motley Fool07:08 16-Feb-25
    In the last month
    GlobeNewswire (Press Release)17:58 14-Feb-25
    GlobeNewswire (Press Release)13:25 14-Feb-25
    Quartz13:14 14-Feb-25
    Yahoo! US09:53 14-Feb-25
    The Motley Fool07:51 14-Feb-25
    Seeking Alpha15:21 13-Feb-25
    Bloomberg Law13:22 13-Feb-25
    GlobeNewswire (Press Release)12:52 13-Feb-25
    TipRanks12:50 13-Feb-25
    The Motley Fool11:21 13-Feb-25
    pharmaphorum05:58 13-Feb-25
    European Pharmaceutical Manufacturer05:41 13-Feb-25
    The West Australian17:55 12-Feb-25
    KELO TV17:39 12-Feb-25
    GlobeNewswire (Press Release)16:42 12-Feb-25
    FiercePharma15:51 12-Feb-25
    Bloomberg Law14:09 12-Feb-25
    GlobeNewswire (Press Release)13:05 12-Feb-25
    Quartz12:50 12-Feb-25
    Forbes12:49 12-Feb-25
    Yahoo! UK & Ireland11:07 12-Feb-25
    PR Newswire (Press Release)21:22 11-Feb-25
    Law36021:22 11-Feb-25
    GlobeNewswire (Press Release)21:01 11-Feb-25
    GlobeNewswire (Press Release)12:18 11-Feb-25
    Forbes08:03 11-Feb-25
    The Telegraph, Calcutta21:09 10-Feb-25
    Minnesota Daily19:35 10-Feb-25
    The Motley Fool19:14 10-Feb-25
    GlobeNewswire (Press Release)13:15 10-Feb-25
    ENDPOINTS12:47 10-Feb-25
    pharmaphorum07:16 10-Feb-25
    Crikey18:41 9-Feb-25
    Australian Financial Review13:04 9-Feb-25
    GlobeNewswire (Press Release)10:40 9-Feb-25
    GlobeNewswire (Press Release)08:14 8-Feb-25
    The Motley Fool06:11 8-Feb-25
    Bangkok Post20:28 7-Feb-25
    GlobeNewswire (Press Release)14:06 7-Feb-25
    European Pharmaceutical Review13:28 7-Feb-25
    Clinical Trials Arena11:37 7-Feb-25
    BusinessDesk11:21 7-Feb-25
    TipRanks09:47 7-Feb-25
    Pharmacy Times09:16 7-Feb-25
    PMLiVE07:29 7-Feb-25
    ENDPOINTS07:23 7-Feb-25
    FierceBiotech05:48 7-Feb-25
    London South East05:19 7-Feb-25
    GlobeNewswire (Press Release)02:52 7-Feb-25
    Manufacturing Chemist02:52 7-Feb-25
    PR Newswire (Press Release)21:29 6-Feb-25
    Power Corridor20:20 6-Feb-25
    Pharmaceutical Technology14:50 6-Feb-25
    GlobeNewswire (Press Release)14:09 6-Feb-25
    Business Wire (Press Release)09:05 6-Feb-25
    TipRanks08:02 6-Feb-25
    Proactive Investors (UK)07:03 6-Feb-25
    The Motley Fool06:21 6-Feb-25
    Business Plus Online05:27 6-Feb-25
    Morningstar05:09 6-Feb-25
    pharmaphorum04:40 6-Feb-25
    GlobeNewswire (Press Release)04:19 6-Feb-25
    TipRanks23:02 5-Feb-25
    view more headlines
    21 Feb 18:22

    About our Novo Nordisk news

    Latest news on Novo Nordisk, a global healthcare company focused on diabetes care, obesity treatment, and other serious chronic diseases. Get updates on Novo Nordisk's products, research, financial performance, and stock price.

    Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. Founded in 1923, the company has grown to become a global leader in diabetes care, with a strong presence in the fields of hemophilia, growth hormone therapy, and obesity treatment. Novo Nordisk's key products include insulin analogs like Tresiba and Levemir, GLP-1 receptor agonists such as Victoza and Ozempic, and obesity drugs like Saxenda and Wegovy.

    Stay informed about the latest developments in Novo Nordisk's research and development pipeline, including updates on clinical trials, regulatory approvals, and new product launches. Our feed covers the company's ongoing efforts to innovate and improve treatments for diabetes, obesity, and other metabolic disorders, such as the development of oral semaglutide and the exploration of novel drug targets.

    In addition to product news, our Novo Nordisk feed keeps you updated on the company's financial performance, including quarterly earnings reports, sales figures, and market share data. We also cover key events and announcements that may impact Novo Nordisk's stock price (NYSE: NVO), such as strategic partnerships, acquisitions, and leadership changes.

    Beyond the business aspects, our feed highlights Novo Nordisk's commitment to corporate social responsibility and sustainability. From initiatives to improve access to diabetes care in developing countries to efforts to reduce the company's environmental footprint, we provide a comprehensive view of Novo Nordisk's impact on global health and society.

    As the prevalence of diabetes and obesity continues to rise worldwide, Novo Nordisk plays a crucial role in addressing these global health challenges. Our Â鶹´«Ã½ feed on Novo Nordisk brings you the most relevant and up-to-date information from reliable sources, helping you stay informed about this innovative and influential healthcare company.


    Publication filters

    Headline Density

    Sorry, no headlines or news topics were found. Please try different keywords.